Regeneron to Extend Payment Terms for Eylea (Aflibercept) Injection

Source: American Academy of Ophthalmology

In response to the COVID-19 pandemic, Regeneron will temporarily extend physician payment terms for Eylea (aflibercept) purchases from authorized distributors to 150 days. This has no impact on current Eylea return policies.

Physicians may be temporarily eligible for payment terms of up to 150 days (previously 100 days), subject to distributor qualification. Ophthalmologists are urged to verify the timing and specific dating terms that apply to their offices with their authorized distributors of record.

Regeneron aims to implement these new temporary terms by April 1, 2020 and to have these new terms apply retroactively for Eylea (vial or prefilled syringe) purchased on or after March 1, 2020. These temporary payment terms are subject to change and will be evaluated as the COVID-19 situation evolves.

“The COVID-19 pandemic is having a significant impact on patients and ophthalmologists. In some cases, it is limiting patient access to essential care,” Anne L. Coleman, MD, PhD, president of the American Academy of Ophthalmology, said in a company news release. “We will continue to work with the healthcare community to find ways to help our patients and colleagues get through this difficult time.  Regeneron’s prompt response to their needs will be extraordinarily beneficial.”

Please contact your specialty distributor with questions or to apply these new terms.

For more on Regeneron’s scientific efforts to help address COVID-19, go to regeneron.com/covid19

For the Academy’s latest coronavirus updates for ophthalmologists, go toaao.org/coronavirus

Related Content